期刊文献+

骨康方君臣佐使药治疗骨质疏松药理机制探讨 被引量:3

Study on the pharmacological mechanism of the monarch,minister,assistant,and guide of Gukang decoction in the treatment of osteoporosis
下载PDF
导出
摘要 目的基于网络药理学分析骨康方中药治疗骨质疏松(OP)的具体作用机制及其作用靶点、通路的异同。方法首先通过数据库以及文献检索分别筛选出骨康方中君臣佐使各药的主要活性成分及其作用靶点;同时利用网络数据库得到OP相关的靶点;通过Venny 2.1分别筛选出君臣佐使-OP的交集靶点;然后通过STRING和Cytoscape软件分别构建骨康方中君臣佐使-OP交集靶点的蛋白相互作用(PPI)网络并筛选出关键靶点;最后通过DAVID数据库分别对君臣佐使-OP的关键靶点进行KEGG通路分析,并使用Venny 2.1对KEGG结果进行交集。结果经交集筛选后获得君臣佐使-OP的关键靶点,其中君药有6个、臣药有30个、佐药有31个和使药有30个,KEGG通路富集结果显示有9条君臣佐使各药关键靶点的共同通路、7条君药所特有的通路、2条臣药特有通路和1条使药特有通路,而佐药无特有的通路。结论骨康方中君臣佐使各药有共同的调节通路,可能通过MAPK通路治疗OP,同时也有各自特殊的调节机制,发挥独特作用。 Objective Based on network pharmacology,this paper analyzes the specific mechanism of monarch,minister,assistant,and guide of Gukang decoction in the treatment of osteoporosis(OP),and discusses the similarities and differences of its target and pathway.Methods First,the main active components and related targets of monarch,minister,assistant,and guide of Gukang decoction were screened through database and literature search.At the same time,the OP-related targets were obtained from the network database.The intersection between targets of monarch,minister,assistant and guide-OP was screened with Venny 2.1.Protein-protein interaction(PPI)networks of intersection targets were constructed with STRING and Cytoscape software,respectively.Finally,the KEGG pathway of key targets were analyzed using DAVID database,and the KEGG result were interleaved with Venny 2.1.Results The key targets of monarch,minister,assistant,and guide-OP were obtained by screening and intersection,including 6 monarch drugs,30 minister drugs,31 assistant drugs,and 30 guide drugs.The enrichment result of KEGG pathway showed that there were 9 common pathways of key targets of monarch,minister,assistant,and guide,7 specific pathways of monarch drugs,2 specific pathways of minister drugs,and 1 specific pathway of guide drugs,but no specific pathway of assistant drugs.Conclusion Monarch,minister,assistant,and guide of Gukang decoction have common regulation pathway,which may treat OP through MAPK pathway.At the same time,they have their own special regulatory mechanism and play a unique role.
作者 梁倩欣 董家铭 谢曼琳 邹艳芳 涂兴明 赵可伟 LIANG Qianxin;DONG Jiaming;XIE Manlin;ZOU Yanfang;TU Xingming;ZHAO Kewei(Guangzhou University of Chinese Medicine, Guangzhou 510006, China;Guangzhou University of Chinese Medicine, the Third Affiliated Hospital, Guangzhou 510378,China)
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2022年第3期440-445,共6页 Chinese Journal of Osteoporosis
基金 国家自然科学基金面上项目(81973633) 广东省中医药管理局重点项目(20173010) 广州中医药大学一流学科研究重点项目(A3-0402-20-415-017) 广东省中医药局单方验方整理研究项目(20183006)。
关键词 骨康方 君臣佐使 骨质疏松 网络药理学 Gukang decoction monarch,minister,assistant,and guide osteoporosis network pharmacology
  • 相关文献

参考文献9

二级参考文献185

共引文献414

同被引文献58

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部